Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome
CA2682661A1
Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity
US2008255185A1
Small-molecule modulators of TRP-P8 activity
US2008286293A1
Promiscuous PAP CD4 T cell epitopes
US2008107667A1
Promiscuous HER-2/Neu CD4 T cell epitopes
RU2509079C2
LOW-MOLECULAR WEIGHT Trp-p8 ACTIVITY MODULATORS
EP1711527A2
Hla-dr-specific antibodies, compositions and methods
WO2005041631A2
Endotheliase-1 ligands
EP1663962A2
Compositions and methods for the treatment of disease associated with trp-p8 expression
CN1823169A
Process for manufacture of nematode-extracted anticoagulant protein (NAP)
CA2514288A1
Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
US2004186060A1
Matriptase inhibitors and methods of use
AU2003267254A1
Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers
AU2003220722A1
Method for preparation and in vivo administration of antigen presenting cell composition
US2004266672A1
Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
AU2002347858A1
Transmembrane serine protease 25
AU4439202A
Composition and method for inducing and immune response against tumor-related antigens
US7413869B2
Method for determining potency of antigenic presenting cell based vaccines
EP1379637A2
Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
AU2002254357A1
Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
